OBIO (Orchestra BioMed Holdings) Future 3-5Y Total Revenue Growth Rate : 12.46 (As of Dec. 15, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Orchestra BioMed Holdings Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Orchestra BioMed Holdings's Future 3-5Y Total Revenue Growth Rate is 12.46.

Competitive Comparison of Orchestra BioMed Holdings's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, Orchestra BioMed Holdings's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orchestra BioMed Holdings's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Orchestra BioMed Holdings's Future 3-5Y Total Revenue Growth Rate falls into.

Orchestra BioMed Holdings (NAS:OBIO) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Orchestra BioMed Holdings Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Orchestra BioMed Holdings's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Orchestra BioMed Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchestra BioMed Holdings Inc (NAS:OBIO) » Definitions » Future 3-5Y Total Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 Union Square Drive,, New Hope, PA, USA, 18938

Website

https://www.orchestrabiomed.com

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Executives

David P Hochman	director, officer: See Remarks	15 WESTON HILL RD., RIVERSIDE CT 06878
Eric S Fain	director	ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Darren Sherman	director, officer: See Remarks	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
William Reed Little	officer: See Remarks	C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
George Papandreou	officer: See Remarks	C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Joshua Aiello	officer: Principal Accounting Officer	150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Yuval Mika	officer: See Remarks	150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Pamela Ann Connealy	director	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Rose Eric A Md	director	161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Andrew Lawrence Taylor	officer: Chief Financial Officer	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Plc Medtronic	10 percent owner	20 ON HATCH, LOWER HATCH STREET, DUBLIN L2 2
Michael Kaswan	officer: Chief Financial Officer	KBL HEALTHCARE ACQUISITION CORP II, 645 MADISON AVENUE, NEW YORK NY 10022
Geoffrey Wade Smith	director	6740 SHADY OAK ROAD, EDEN PRAIRIE MN 55344
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014